Clinical trials
Atopic Dermatitis clinical trials
Below are recruiting atopic dermatitis clinical trials, each written for real people, not researchers. We’re tracking 176 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06850311RecruitingPhase 2/Phase 3
Herbal ointment for mild to severe eczema
This trial tests whether a special herbal ointment can help treat atopic dermatitis (eczema). It is for adults with mild, moderate, or severe eczema covering less than 10% of their body surface. The ointment is applied directly to the skin, and participants will also use a gentle, fragrance-free moisturizer.
New Taipei CityAges 18–65 - NCT07330934RecruitingPhase 2
Study of IBI356 for moderate to severe eczema
This study tests a new medication called IBI356 for people with moderate to severe eczema that hasn't improved with standard creams. The goal is to see if this medicine can safely reduce the redness, itching, and rash.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07333378Recruiting
Keeping vernix on newborns to prevent eczema
This study tests whether leaving the white, waxy coating (vernix caseosa) on a newborn’s skin after birth can help prevent the development of eczema (atopic dermatitis) in early childhood. It compares standard bathing practices with preserving this natural skin barrier.
Las Condes, RMAges birth+ - NCT07316465Recruiting
Tracking immune markers in newborns at risk for eczema
This study follows newborns for two years to see how their immune system develops, especially if they have a family history of eczema, asthma, or hay fever. Researchers want to learn if certain immune markers appear early in babies who later develop eczema.
Jette, Brussels CapitalAges 1 hour–2 years - NCT07298395RecruitingPhase 2
Study of ENV-294 for moderate-to-severe eczema
This trial tests an experimental cream or pill called ENV-294 in adults whose eczema is moderate to severe and hasn't gotten better with standard creams. It aims to see if ENV-294 can help control symptoms like itching and skin redness.
Birmingham, AlabamaAges 18–75 - NCT06882148Recruiting
How long do eczema patients stay on targeted therapies?
This study looks at how long people with moderate to severe eczema stay on newer targeted medicines (biologics or pills). By reviewing medical records, researchers hope to learn which treatments work best over time and how they are used in real life.
RomeAges 18 years+ - NCT03549416Recruiting
BioDay Registry collects information on new eczema treatments
This registry study collects questionnaire information from people with atopic dermatitis (eczema) who are starting newer whole-body (systemic) treatments. It may help doctors better understand how these new options work in everyday care.
Nijmegen, GelderlandAges birth+ - NCT07230483RecruitingPhase 2
Long-term safety of CM512 for atopic dermatitis
This study is for people who have already completed a previous study of CM512 for atopic dermatitis. It will check if the medicine is safe and works well over a longer period.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07235384RecruitingPhase 1
Zai Lab tests ZL-1503 for moderate to severe eczema
This study tests a new medication called ZL-1503 for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The trial will check if the drug is safe and how well it works.
Woolloongabba, QueenslandAges 18–65 - NCT07223697RecruitingPhase 2
Long-term safety of Afimkibart for eczema patients
This study tests the long-term safety and effectiveness of a medicine called Afimkibart for people with atopic dermatitis (eczema). It is for people who already completed a previous study of this medicine and had at least a 50% improvement in their eczema.
Los Angeles, CaliforniaAges 18 years+ - NCT07204561Recruiting
CeraVe cream for keeping skin hydrated after atopic dermatitis treatment
This trial tests whether using CeraVe moisturizer can keep your skin hydrated and prevent flare-ups after your eczema has been cleared with a steroid treatment. It is for adults with mild to moderate eczema that gets better with steroids.
Roma, RMAges 18–99 - NCT07193589RecruitingPhase 2
Testing ZL-82 tablets for moderate to severe eczema
This study tests if an oral tablet called ZL-82 can help people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to other treatments. It aims to find a new option for controlling this chronic skin condition.
Chengdu, SichuanAges 18–75 - NCT07180511Enrolling by invitationPhase 3
A study of QY201 tablets for moderate to severe eczema
This trial tests a new pill called QY201 for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. It aims to see if QY201 can help control itching and skin inflammation.
Hangzhou, ZhejiangAges 18–75 - NCT06587685RecruitingPhase 3
PG-011 gel for eczema in teens and adults
This trial tests a new gel called PG-011 for people with mild to moderate eczema (atopic dermatitis). The gel is applied to the skin, and the study will check if it helps improve symptoms safely.
Shenyang, LiaoningAges 12–75 - NCT07056569Recruiting
Testing a dermatitis cream for adults and children with eczema
This study tests a medical cream for people with atopic or contact dermatitis (eczema). It aims to see how well the cream works and if it is safe for both adults and children over 6 months old.
MilanAges 6 months–65 years - NCT06636240Recruiting
Mulberry for eczema in children
This study tests whether mulberry extract could help improve eczema symptoms in children. It is a small, early trial to see if this natural prebiotic is safe and helpful.
New Taipei City, TaiwanAges 6–17 - NCT07042126RecruitingPhase 3
Testing 611 for Teen Eczema (moderate to severe)
This trial tests a new injectable medicine (611) for teenagers with moderate to severe eczema that hasn't been helped enough by creams. It aims to see if the drug can safely reduce itching and skin symptoms.
Beijing, Beijing MunicipalityAges 12–17 - NCT07037901RecruitingPhase 2
Testing IMG-007 for moderate-to-severe eczema
This study tests a new medicine called IMG-007 for adults with moderate-to-severe eczema (atopic dermatitis) that hasn't gotten better with standard creams. The goal is to see if it safely reduces itching and skin symptoms.
Lancaster, CaliforniaAges 18–74 - NCT07022288Recruiting
Study of La Roche-Posay cream for mild facial eczema
This study tests whether a specific soothing moisturizer (La Roche-Posay B5 cream) helps people with mild, stable facial eczema. It is a simple, low-risk trial using a cream you can apply at home.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07015762RecruitingPhase 1
Testing IBI3002 for moderate-to-severe eczema
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
Suzhou, JiangsuAges 18–65 - NCT07003425RecruitingPhase 2
Long-term safety and effectiveness of APG777 for eczema
This study looks at the long-term safety and how well APG777 works for people with eczema (atopic dermatitis). It is for people who have already completed treatment with APG777 in an earlier study and may benefit from continuing it.
Fountain Valley, CaliforniaAges 18 years+ - NCT06313333Recruiting
National registry for moderate to severe adult atopic dermatitis
This registry tracks adults with moderate to severe atopic dermatitis (eczema) over time. It helps doctors learn more about the disease and how treatments work in real life.
Brescia, BresciaAges 18 years+ - NCT06947993RecruitingPhase 2
Study of a new treatment for moderate to severe eczema
This study tests an experimental treatment for people with moderate to severe eczema that has lasted at least a year. It aims to see if the new medicine can help control symptoms better than current options.
Birmingham, AlabamaAges 18–100 - NCT06947980RecruitingPhase 2
Study of CM512 for moderate-to-severe atopic dermatitis
This trial tests a new treatment called CM512 for people with moderate-to-severe eczema (atopic dermatitis). It aims to see if the drug can improve skin symptoms like itching and rash.
BeijingAges 18–75
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for atopic dermatitis?
- Yes. Clin2 currently lists 176 recruiting atopic dermatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a atopic dermatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a atopic dermatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.